M2Gen® Appoints New Senior Vice President and Chief Financial Officer

September 23, 2016

TAMPA, Fla. Joseph R. Smith has been named Senior Vice President and Chief Financial Officer at M2Gen®, Moffitt Cancer Center’s wholly owned, for-profit subsidiary.  M2Gen is a health informatics solutions company focused on advancing personalized medicine by combining high quality molecular data and clinical data in an informatics environment to accelerate discovery and delivery of personalized medicine.  In his role as SVP and CFO, Joe will help lead the organization as it develops and executes its growth and development activities.

Mr. Smith joined M2Gen at the beginning of 2016 working in a business and financial consulting role.  “Joe’s contribution to strategy, development of processes and procedures and financial discipline has been and will continue to be invaluable to the development of M2Gen as an organization now and into the future.  We are excited to have someone of Joe’s caliber and business experience joins the organization,” said Bill Dalton, Ph.D., M.D., CEO of M2Gen.

“M2Gen is at an inflection point in its growth and the opportunity that lies ahead,” said Smith. “Working with the distinguished cancer centers around the country that make up the Oncology Research Information Exchange Network ® (ORIEN) and the truly dedicated team here at M2Gen to aggregate clinical and molecular data into one large database for study is incredibly exciting.  I am proud to be associated with this effort to accelerate the discovery and development of personalized medicines in a new and exciting way.”

Before joining M2Gen Smith, a CPA was a partner at Deloitte and has held CFO and COO roles in public and private companies in the health and education business sectors.  Mr. Smith has a Bachelor of Science in Business Administration degree from the University of Florida.

*Photo available upon request

About M2Gen®

M2Gen® is a health informatics solutions company focused on accelerating the discovery and development of personalized medicines. M2Gen partners with the nation’s leading cancer centers through ORIEN to create a large, cancer-focused data warehouse linking clinical and molecular data. Using this information, M2Gen helps biopharmaceutical companies address the greatest challenges in oncology drug development.  For more information, visit www.m2gen.com.